Is MOTS-c Approved? What the Evidence Shows

Nearly every peptide discussed in this context is either a copy of something the body makes from its nuclear genome, or a synthetic molecule designed to imitate one. MOTS-c is neither. Its instructions are written in mitochondrial DNA — the small, separate genome that mitochondria carry — and that is what makes it genuinely unusual.

Where it comes from

Mitochondria have their own circular genome, a remnant of the bacterial ancestry of the organelle. For a long time it was assumed to encode only a handful of respiratory-chain components and the RNAs needed to build them.

MOTS-c sits inside the 12S rRNA gene. It is 16 amino acids long, and its name is an acronym of that location: Mitochondrial ORF of the Twelve S rRNA type-c. The 2015 paper in Cell Metabolism that described it made the case that mitochondria are not only power plants but also send signals that regulate the rest of the cell.

What it appears to do

The 2015 work traced a mechanism rather than just an association:

Step	What was reported
Target pathway	The folate–methionine cycle, with downstream effects on purine biosynthesis
Consequence	Accumulation of AICAR, an endogenous AMPK activator
Effect	AMPK activation, shifting cells toward energy production rather than storage
In mice	Reduced diet-induced obesity and improved insulin sensitivity

AMPK is the cell’s low-energy sensor. It is the same pathway that exercise and caloric restriction engage, which is why MOTS-c is often described as an “exercise-mimetic” candidate — a description that runs ahead of the evidence, but that does correctly identify the pathway.

The exercise connection, stated carefully

A 2021 paper in Nature Communications reported that MOTS-c is exercise-induced and acts as a regulator of age-dependent physical decline and muscle homeostasis. A 2022 review in Diabetes & Metabolism Journal placed this within mitohormesis — the idea that mild mitochondrial stress produces an adaptive, beneficial response.

The direction of that finding matters, and it is routinely reversed in summaries. What is reported is:

Exercise → mitochondrial stress → more MOTS-c → metabolic adaptation.

What is not established is the reverse inference — that administering MOTS-c delivers the adaptations that exercise produces. Those are different claims, and only the first one has the supporting data.

Is MOTS-c an approved medicine anywhere?

No, and the human evidence is the part worth being precise about. The human data are largely observational: MOTS-c has been measured in people, and its levels correlate with exercise, age and metabolic state. Correlation in measured levels is a long way from a controlled trial of administration.

The 2023 review in Frontiers in Endocrinology frames MOTS-c as promising for therapeutic exploitation — which is an accurate description of a molecule at that stage, and also an admission that the exploitation has not happened yet. There is no MOTS-c product with a marketing authorisation in any jurisdiction, and no completed randomised controlled trial establishing clinical efficacy or long-term safety in humans.

So the honest summary is: a real endogenous signalling peptide, a well-described mechanism, strong animal results, and an unfinished human story.

The July 2026 recommendation

On 23 July 2026 the FDA’s Pharmacy Compounding Advisory Committee recommended that MOTS-c be added to the 503A bulk drug substances list. This is worth stating carefully, because it is easily misread as the missing approval. It is not. The committee is advisory, the recommendation is the first of four stages, and the three that follow have no deadline — what still has to happen.

Nothing in it converts observational human data into trial evidence. A substance can be eligible for compounding and still have no completed randomised trial behind it, which remains the position here.

Practical notes

Nothing about the biology changes the handling. As a lyophilised peptide it follows the same stability rules as any other — stable dry, much less stable in solution — which is set out in peptide storage. How often something is administered is a function of how long it survives in circulation, covered in peptide half-life — where MOTS-c is one of the rows with no published human figure, because measuring endogenous levels is not the same experiment as measuring clearance after administration. Turning a vial into a measured volume is reconstitution arithmetic or one pass through the reconstitution calculator.

The reason to keep records for a compound at this stage of evidence is not that the records prove anything. It is that when the human data eventually arrive, you want to know accurately what you did — and memory over a protocol lasting months is not a reliable instrument.

Frequently asked questions

What is MOTS-c?

A 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene rather than in nuclear DNA. It was described in 2015 in Cell Metabolism as a regulator of metabolic homeostasis, acting largely through the AMPK pathway.

Is MOTS-c an approved medicine?

No. There is no MOTS-c product with a marketing authorisation anywhere. The published work is in cells, mice and observational human measurements — not completed randomised trials establishing clinical efficacy or long-term safety.

Is it true that exercise raises MOTS-c?

That is what the research reports. A 2021 Nature Communications paper described MOTS-c as an exercise-induced, mitochondrially encoded regulator of age-dependent physical decline and muscle homeostasis. Note the direction: exercise is the stimulus that raises the peptide, which is not the same as showing that injecting the peptide reproduces exercise.

Does MOTS-c help with weight loss?

In mice, MOTS-c administration reduced diet-induced obesity and insulin resistance. That result has not been reproduced as a clinical outcome in humans in a completed trial, so it should be read as a finding in an animal model rather than an established human effect.

Sources

MOTS-cMitochondriaMetabolismExerciseEvidence